Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Simple Search

Search Type: Criteria:

You could also try: mistake (35), fault (22), slip (31)

Lenvatinib(59kg or less)

Description: Chemotherapy Protocol HEPATOCELLULAR CANCER LENVATINIB (59kg or less) Regimen • Hepatocellular – Lenvatinib Indication • Lenvatinib is indicated where either; - the patient has a
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Hepatobiliary/Lenvatinib-59kg-or-less-.pdf

Cisplatin-Gemcitabine Version 1.2

Description: Chemotherapy Protocol BILIARY TRACT CANCER CISPLATIN-GEMCITABINE Regimen Biliary Tract Cancer – Cisplatin-Gemcitabine Indication First line therapy of locally advanced / metastatic
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Hepatobiliary/Cisplatin-Gemcitabine-Version-12.pdf

Pembrolizumab (200mg)

Description: Regimen Chemotherapy Protocol HEAD AND NECK CANCER Pembrolizumab (200mg) • Head and Neck – Pembrolizumab (200mg) Indication • Pembrolizumab is recommended in in adult
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Headandneckcancer/Pembrolizumab-200mg.pdf

Nivolumab_240mg

Description: Chemotherapy Protocol HEAD AND NECK CANCER Nivolumab (240mg-14 days) Regimen • Head and Neck – Nivolumab (240mg-14 days) Indication • The treatment
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Headandneckcancer/Nivolumab-240mg.pdf

Nivolumab

Description: Chemotherapy Protocol HEAD AND NECK CANCER Nivolumab Regimen • Head and Neck – Nivolumab Indication • The treatment of recurrent or metastatic squamous cell
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Headandneckcancer/Nivolumab.pdf

Pembrolizumab (400mg) head and neck

Description: Chemotherapy Protocol HEAD AND NECK CANCER Pembrolizumab (400mg) Regimen • Head and Neck – Pembrolizumab (400mg) Indication • Pembrolizumab is recommended in in adult
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Headandneckcancer/Pembrolizumab-400mg-head-and-neck.pdf

HSCTAlemtuzumabFludarabineMelphalan-VUD-Methotrexate-GvHD

Description: Chemotherapy Protocol HAEMATOLOGY – HSCT ALLOGRAFT ALEMTUZUMAB-FLUDARABINE-MELPHALAN-METHOTREXATE (GVHD) Volunteer Unrelated Donor (VUD) Conditioning This regimen will only be available
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Transplant/HSCTAlemtuzumabFludarabineMelphalan-VUD-Methotrexate-GvHD.pdf

HSCTAlemtuzumabFludarabineMelphalan-Related_Methotrexate_GvHD

Description: Chemotherapy Protocol HAEMATOLOGY – HSCT ALLOGRAFT ALEMTUZUMAB-FLUDARABINE-MELPHALAN-METHOTREXATE (GvHD) RELATED DONOR CONDITIONING This regimen will only be available to prescribe
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Transplant/HSCTAlemtuzumabFludarabineMelphalan-Related-Methotrexate-GvHD.pdf

HSCTAlemtuzumabBusulphan-08-Fludarabine-VUD-Methotrexate-GvHD

Description: Chemotherapy Protocol HAEMATOLOGY – HSCT ALLOGRAFT ALEMTUZUMAB-BUSULFAN (8 doses)-FLUDARABINE-METHOTREXATE (GvHD) Volunteer Unrelated Donor (VUD) CONDITIONING This regimen will only
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Transplant/HSCTAlemtuzumabBusulphan-8-Fludarabine-VUD-Methotrexate-GvHD.pdf

HSCTAlemtuzumabBusulphan-12-Fludarabine-VUD-Methotrexate-GvHD

Description: Chemotherapy Protocol HAEMATOLOGY – HSCT ALLOGRAFT ALEMTUZUMAB-BUSULFAN (12 doses)-FLUDARABINE-METHOTREXATE (GvHD) Volunteer Unrelated Donor (VUD) CONDITIONING This regimen will only
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Transplant/HSCTAlemtuzumabBusulphan-12-Fludarabine-VUD-Methotrexate-GvHD.pdf

481 to 490 of 630

Previous … 47 48 49 50 51 … Next